[go: up one dir, main page]

IN2012DN00908A - - Google Patents

Info

Publication number
IN2012DN00908A
IN2012DN00908A IN908DEN2012A IN2012DN00908A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A IN 908DEN2012 A IN908DEN2012 A IN 908DEN2012A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A
Authority
IN
India
Prior art keywords
polypeptides
factor
modified factor
methods
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Brooks Alan
Patel Chandra
Jiang Xiaoqiao
Gritzan Uwe
Apeler Heiner
Wangjun
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of IN2012DN00908A publication Critical patent/IN2012DN00908A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN908DEN2012 2009-07-31 2010-08-02 IN2012DN00908A (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00908A true IN2012DN00908A (no) 2015-04-03

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
IN908DEN2012 IN2012DN00908A (no) 2009-07-31 2010-08-02

Country Status (21)

Country Link
US (1) US20120164130A1 (no)
EP (1) EP2461821A4 (no)
JP (1) JP2013500726A (no)
KR (1) KR20120060209A (no)
CN (1) CN102573890A (no)
AU (1) AU2010278721A1 (no)
BR (1) BR112012002072A2 (no)
CA (1) CA2769258A1 (no)
CL (1) CL2012000238A1 (no)
CR (1) CR20120052A (no)
CU (3) CU20120018A7 (no)
DO (1) DOP2012000030A (no)
EA (1) EA201290069A1 (no)
EC (1) ECSP12011637A (no)
GT (1) GT201200023A (no)
IN (1) IN2012DN00908A (no)
MX (1) MX2012001346A (no)
PE (1) PE20121643A1 (no)
SG (1) SG178119A1 (no)
WO (1) WO2011014890A1 (no)
ZA (1) ZA201200716B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655639T3 (es) 2006-12-15 2018-02-21 Baxalta GmbH Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada
CA2737094C (en) 2008-09-15 2018-02-20 Paolo Simioni Factor ix polypeptide mutant, its uses and a method for its production
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
EP2459226B1 (en) 2009-07-27 2016-06-29 Lipoxen Technologies Limited Glycopolysialylation of proteins other than blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
BR112013001611B1 (pt) * 2010-07-30 2022-05-10 Takeda Pharmaceutical Company Limited Método para conjugar um polímero solúvel em água a uma fração de carboidrato oxidado de uma proteína terapêutica, proteína terapêutica modificada, método para formar uma ligação oxima entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo amino-óxi ativo emétodo para formar uma ligação hidrazona entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo hidrazida ativo
EA032056B1 (ru) 2010-12-22 2019-04-30 Баксалта Инкорпорейтид Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты)
RU2617764C2 (ru) * 2011-12-19 2017-04-26 Дилафор Аб Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение
BR112015011462A2 (pt) * 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
PL2970424T3 (pl) * 2013-03-13 2017-11-30 Eli Lilly And Company Zmodyfikowane polipeptydy leptyny psowatych
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
EP4566666A3 (en) 2016-07-27 2025-09-17 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス，インコーポレーテッド 第ｉｘ因子を発現するための組成物及び方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044982A1 (en) * 2001-04-25 2003-03-06 Kenneth Chien Method to treat hemophilia by hepatic gene transfer of factor VIII/IX with vesicle vector
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005055950A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated factor ix
WO2007149406A2 (en) * 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
DOP2012000030A (es) 2012-02-29
CU20120018A7 (es) 2012-06-21
WO2011014890A1 (en) 2011-02-03
CL2012000238A1 (es) 2012-10-05
PE20121643A1 (es) 2012-11-25
ECSP12011637A (es) 2012-02-29
MX2012001346A (es) 2012-02-17
CU20130057A7 (es) 2013-06-28
SG178119A1 (en) 2012-03-29
GT201200023A (es) 2014-01-27
EP2461821A1 (en) 2012-06-13
BR112012002072A2 (pt) 2016-11-08
JP2013500726A (ja) 2013-01-10
CR20120052A (es) 2012-06-04
CU20130058A7 (es) 2013-06-28
US20120164130A1 (en) 2012-06-28
EP2461821A4 (en) 2013-07-03
CA2769258A1 (en) 2011-02-03
CN102573890A (zh) 2012-07-11
KR20120060209A (ko) 2012-06-11
ZA201200716B (en) 2013-07-31
EA201290069A1 (ru) 2012-07-30
AU2010278721A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
IN2012DN00908A (no)
MX2011007930A (es) Conjugados de insulina cristalina.
MY192475A (en) Modified factor ix polypeptides and uses thereof
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
GEP20146056B (en) Acylated glucagon analogues
MX355543B (es) Macrociclos peptidomiméticos.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
IN2012DN03883A (no)
IN2012DN02177A (no)
PH12012501263B1 (en) Oxyntomodulin peptide analogue
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2010010457A (es) Vectores recombinantes de rinovirus.
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
PH12014501200B1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX2011008179A (es) Peptidos para vacuna.
EP2552462A4 (en) CCN3 THERAPEUTIC PEPTIDES AND THEIR ANALOGS